News in brief: SGLT2 inhibitor approved for CKD; Monash researchers find key to insulin resistance; COVID-19 vax boosters needed for some patients: ATAGI

SGLT2 inhibitor approved as first new treatment for CKD in 20 years Dapagliflozin (Forxiga) has been TGA approved to reduce the risk of worsening kidney function in adults with proteinuric chronic kidney disease. Professor Carol Pollock, renal research lead at the Kolling Institute, Royal North Shore Hospital, said the new indication represents a significant milestone ...

Already a member?

Login to keep reading.

© 2021 the limbic